StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3037% below fair value
$3.36−0.11 (-3.17%)

Close on Nov 18, 2026Market cap $1.15BP/E 84.0Yield –

GoodRx revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

GoodRx's revenue for the twelve months ending Jun 30, 2026 was $785.23M, down 1.8% year over year. For fiscal 2025 it was $796.85M, up 0.6% from the year before. The highest annual figure on record is $796.85M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$796.85M+0.6%
FY2024Dec 31, 2024$792.32M+5.6%
FY2023Dec 31, 2023$750.27M-2.1%
FY2022Dec 31, 2022$766.55M+2.8%
FY2021Dec 31, 2021$745.42M+35.4%
FY2020Dec 31, 2020$550.70M+41.9%
FY2019Dec 31, 2019$388.22M+55.6%
FY2018Dec 31, 2018$249.52M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$200.41M-1.3%
Q1 FY2026Mar 31, 2026$194.01M-4.4%
Q4 FY2025Dec 31, 2025$194.79M-1.9%
Q3 FY2025Sep 30, 2025$196.03M+0.4%
Q2 FY2025Jun 30, 2025$203.07M+1.2%
Q1 FY2025Mar 31, 2025$202.97M+2.6%
Q4 FY2024Dec 31, 2024$198.58M+1.0%
Q3 FY2024Sep 30, 2024$195.25M+8.5%
Q2 FY2024Jun 30, 2024$200.61M+5.8%
Q1 FY2024Mar 31, 2024$197.88M+7.6%
Q4 FY2023Dec 31, 2023$196.64M+6.8%
Q3 FY2023Sep 30, 2023$179.96M-3.9%
Q2 FY2023Jun 30, 2023$189.68M-1.1%
Q1 FY2023Mar 31, 2023$183.99M-9.5%
Q4 FY2022Dec 31, 2022$184.11M-13.7%
Q3 FY2022Sep 30, 2022$187.32M-4.0%
Q2 FY2022Jun 30, 2022$191.80M+8.6%
Q1 FY2022Mar 31, 2022$203.33M+26.7%
Q4 FY2021Dec 31, 2021$213.26M+38.9%
Q3 FY2021Sep 30, 2021$195.10M+38.9%
Q2 FY2021Jun 30, 2021$176.64M+43.3%
Q1 FY2021Mar 31, 2021$160.43M+20.3%
Q4 FY2020Dec 31, 2020$153.54M+35.6%
Q3 FY2020Sep 30, 2020$140.45M+38.0%
Q2 FY2020Jun 30, 2020$123.30M–
Q1 FY2020Mar 31, 2020$133.41M–
Q4 FY2019Dec 31, 2019$113.26M–
Q3 FY2019Sep 30, 2019$101.75M–

More GoodRx figures

See a number that looks wrong?